The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Alnylam elects Fanucci to board

December 9, 2010 5:36 am | by Mass High Tech: The Journal of New England Technology | News | Comments

RNAi-focused therapeutics firm Alnylam Pharmaceuticals Inc. has elected Marsha H. Fanucci, former chief financial officer of fellow Cambridge-based biotechnology company Millennium Pharmaceuticals Inc., to its board of directors.

Alere gets OK for $50M stock buyback

December 9, 2010 5:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

The board of directors at Waltham-based Alere Inc., the healthcare management company formerly known as Inverness Medical Innovations, has given it approval of a stock repurchase program for up to $50 million worth of its common or preferred stock.

Manufacturing Growth Forecasted for 2011

December 9, 2010 5:35 am | by Material Handling Industry of America | News | Comments

The U.S. manufacturing sector will grow in 2011, with manufacturing revenue increasing by 5.6% according to the Institute for Supply Management (ISM) semi-annual forecast released.The overall forecast projects optimism about the U.S. economy for 2011.


VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Graft...

December 9, 2010 5:35 am | by Bio-Medicine.Org | News | Comments

ANN ARBOR, Mich., Dec. 9, 2010 /- Terumo Cardiovascular Systems has announced the introduction of the VirtuoSaph® Plus Endoscopic Vessel Harvesting System following clearance by the U.S. Food and Drug Administration (FDA). (Logo:


Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer

December 9, 2010 5:34 am | by Bio-Medicine.Org | News | Comments

SANTA ROSA, Calif., Dec. 9, 2010 /- Osseon Therapeutics, Inc. today named Mr. Gary Coughlen, CPA as the company's Chief Financial Officer, effective immediately. Mr. Coughlen was most recently the Chief Financial Officer of PolyRemedy, Inc., a private-equity medical device company focused...


Aromatase Inhibitors Increased Risk of Heart Disease in Postmenopausal Women with Breast Cancer

December 9, 2010 5:34 am | by AACR | News | Comments

SAN ANTONIO - Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.


Obese Women with ER-positive/HER2-negative Breast Cancer Have Poorer Survival Rates

December 9, 2010 5:34 am | by AACR | News | Comments

SAN ANTONIO - Obesity was associated with worse overall and disease-free survival in women with operable breast cancer treated with adjuvant chemotherapy, but for the first time, researchers observed this finding in only a specific subset of patients – those with estrogen receptor...


Estrogen Alone is Effective for Reducing Breast Cancer Risk

December 9, 2010 5:34 am | by AACR | News | Comments

SAN ANTONIO - While endogenous estrogen (i.e., estrogen produced by ovaries and by other tissues) does have a well-known carcinogenic impact, hormone replacement therapy (HRT) utilizing estrogen alone (the exogenous estrogen) provides a protective effect in reducing breast cancer risk,...


PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutane...

December 9, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

MAHWAH, N.J., Dec. 9, 2010 /- MAQUET Cardiovascular, the leading distributor of intra-aortic balloon pumps (IABP) worldwide, learned that the PROTECT II clinical trial, sponsored by Abiomed, that compared the safety and effectiveness of the Impella percutaneous ventricular assist device...


HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock

December 9, 2010 5:33 am | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 9, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today its intention to offer, subject to market and other conditions, $100 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to...


New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations

December 9, 2010 5:32 am | by Bio-Medicine.Org | News | Comments

RIDGEFIELD, Conn., Dec. 9, 2010 /- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free...


Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity

December 9, 2010 5:31 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Dec. 9, 2010 /- Customers using Elekta's MOSAIQ® oncology information system (OIS) experience success with seamless integration to Varian's TrueBeam ™ system for radiation therapy delivery. The MOSAIQ interface to this linear accelerator is the most recent example of...


States Now Fund Majority of Human Embryonic Stem Cell Research

December 9, 2010 4:33 am | by Georgia Tech Institute of Technology | News | Comments

States, not the federal government, now fund the majority of human embryonic stem cell research conducted in the United States, according to a study by Aaron Levine in the journal Nature Biotechnology.  In addition, much of the research performed in the states could likely have been...

Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test

December 9, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

ALISO VIEJO, Calif., Dec. 9, 2010 /- Clarient, Inc. (Nasdaq: CLRT ), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of Mammostrat, a patented, novel test designed to help quantify the...


Docs show Calif.'s worldwide execution drug search

December 9, 2010 1:45 am | by PAUL ELIAS - Associated Press - Associated Press | News | Comments

The e-mail from one California prison official to another almost reads like something out of a spy novel: "May have a secret and important mission for you."Department of Corrections and Rehabilitation undersecretary Scott Kernan sent that message to assistant secretary Anthony Chaus on Sept....


You may login with either your assigned username or your e-mail address.
The password field is case sensitive.